Acolbifene
Acolbifene (INNTooltip International Nonproprietary Name) (developmental code names EM-652, SCH-57068) is a nonsteroidal selective estrogen receptor modulator (SERM) which, as of 2015, is in phase III clinical trials for the treatment of breast cancer.[1][2] This antineoplastic or immunomodulatory drug article is a stub.You can help Wikipedia by expanding it.